BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

825 related articles for article (PubMed ID: 34061144)

  • 1. Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
    Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
    JAMA; 2021 Jun; 325(21):2178-2187. PubMed ID: 34061144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial.
    Furuta S; Sugiyama T; Umibe T; Kaneko Y; Amano K; Kurasawa K; Nakagomi D; Hiraguri M; Hanaoka H; Sato Y; Ikeda K; Nakajima H;
    BMJ Open; 2017 Dec; 7(12):e018748. PubMed ID: 29247107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
    Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
    Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
    Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
    Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avacopan for the Treatment of ANCA-Associated Vasculitis.
    Jayne DRW; Merkel PA; Schall TJ; Bekker P;
    N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
    Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
    N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
    Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
    N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
    Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
    Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Thietart S; Karras A; Augusto JF; Philipponnet C; Carron PL; Delbrel X; Mesbah R; Blaison G; Duffau P; El Karoui K; Smets P; London J; Mouthon L; Guillevin L; Terrier B; Puéchal X;
    JAMA Netw Open; 2022 Jul; 5(7):e2220925. PubMed ID: 35802372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of remission induction therapy for ANCA-associated vasculitis in the elderly.
    Aqeel F; Xu L; Salas A; Wen Y; Eid SM; Geetha D
    Clin Rheumatol; 2023 Sep; 42(9):2427-2435. PubMed ID: 37225927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential Therapy for Remission Induction in Severe Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis.
    Kant S; Habbach A; Gapud EJ; Manno RL; Gattu R; Seo P; Geetha D
    Am J Nephrol; 2019; 50(5):386-391. PubMed ID: 31593967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
    Smith RM; Jones RB; Specks U; Bond S; Nodale M; Aljayyousi R; Andrews J; Bruchfeld A; Camilleri B; Carette S; Cheung CK; Derebail V; Doulton T; Forbess L; Fujimoto S; Furuta S; Gewurz-Singer O; Harper L; Ito-Ihara T; Khalidi N; Klocke R; Koening C; Komagata Y; Langford C; Lanyon P; Luqmani RA; Makino H; McAlear CA; Monach P; Moreland LW; Mynard K; Nachman P; Pagnoux C; Pearce F; Peh CA; Pusey C; Ranganathan D; Rhee RL; Spiera R; Sreih AG; Tesar V; Walters G; Weisman MH; Wroe C; Merkel PA; Jayne D; ;
    Ann Rheum Dis; 2020 Sep; 79(9):1243-1249. PubMed ID: 32581088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
    Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
    Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
    Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
    N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
    Soulsby WD
    ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
    Stone JH; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Turkiewicz A; Tchao NK; Webber L; Ding L; Sejismundo LP; Mieras K; Weitzenkamp D; Ikle D; Seyfert-Margolis V; Mueller M; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh KA; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Specks U;
    N Engl J Med; 2010 Jul; 363(3):221-32. PubMed ID: 20647199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab for treatment of severe renal disease in ANCA associated vasculitis.
    Geetha D; Hruskova Z; Segelmark M; Hogan J; Morgan MD; Cavero T; Eriksson P; Seo P; Manno RL; Dale J; Harper L; Tesar V; Jayne DR
    J Nephrol; 2016 Apr; 29(2):195-201. PubMed ID: 25986390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
    Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
    J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.